The U.S. Food and Drug Administration has proposed a new Clinical Trial Notification Pathway in its fiscal year 2027 budget, aiming to make it faster and easier for innovative medications to reach patients. The proposal was included on page 26 of the FDA’s budget pitch, which was released last week as part of the President's overall budget plan.
According to the FDA, "The U.S. has longer timelines and a greater regulatory burden [for beginning drug testing in humans] because of the preclinical work and investigational process" which consists of "duplicative and time-consuming requirements." The current Investigational New Drug (IND) process requires sponsors to compile extensive toxicology, pharmacology, and manufacturing data before starting first-in-human trials, triggering a mandatory 30-day review period by the FDA in addition to Institutional Review Board approval.
Regulatory compliance attorney Lauren Hartsmith said, "no study-specific activities may begin before the IND is in effect and an IRB has reviewed and approved the research. This means study-specific activities such as advertising, eligibility screening, and seeking informed consent are prohibited during the 30-day IND hold. The IND waiting period can be particularly challenging in Phase I research, where timelines are especially tight."
The article highlights Australia’s Clinical Trial Notification system as an alternative model that delegates scientific and ethical review to local committees rather than requiring national regulator sign-off before trials begin. This approach allows manufacturers to start human trials within weeks instead of facing lengthy delays. China is also noted for decentralizing its clinical trial system and attracting early-stage biopharmaceutical research due to lower labor costs.
The proposal comes amid concerns that overregulation is pushing clinical trials abroad and that Chinese clinical trial volume is beginning to surpass that of the U.S., raising worries among American policymakers about losing global leadership in pharmaceutical innovation. The Taxpayers Protection Alliance recently reported that reforms beyond early-stage changes are needed, including international regulatory reciprocity and greater use of historical data in approvals.
Further details on this proposal can be found on the official roster page.
